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Increases in aortic stiffness and wave reflections are associated with increased cardiovascular (CV) risk and have a major impact on prevalence, incidence, and severity of hypertension, particularly in older treated populations. In elderly subjects with systolic hypertension, these 2 parameters make significant contributions to the persistence of increased CV morbidity and mortality.
In the past, systolic blood pressure (SBP) and pulse pressure (PP) levels, adjusted for age, were considered as the main indication for antihypertensive drug therapy. Increased aortic stiffness was not an indication for any specific therapeutic approach. Nowadays, in elderly subjects, even those treated for hypertension, aortic stiffness remains strongly associated with elevated CV morbidity and mortality, and is incremental to elevated SBP. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] It is therefore important to evaluate the role of aortic stiffness and wave reflections in the context of the aging process and to investigate their different and contrasting effects in hypertensive men and women.
The age-related increase in aortic stiffness 3, 12 is nonlinear and is more pronounced beyond 55-60 years of age. The increase per year before age 50 is approximately 100 mm/s (i.e., an annual increase of approximately 1%) and rises markedly to an annual increase of over 150 mm/s after age 60. Arterial stiffness can be easily evaluated from pulse wave velocity (PWV) measurements. Calculation involves determining the ratio between the distance and the timing of 2 distinct arterial sites, usually defined from the carotid and femoral arteries ( Figure 1 ). Other territories, such as those of the upper and lower limbs, may also be used to investigate arterial stiffness.
PP-amplification, i.e., the ratio between carotid and brachial PP 1 is used to study wave reflections. To understand this ratio, it is necessary to understand that in a given hydraulic system, loss of energy should be minimal as the pressure travels from the pump toward the periphery. Within the arterial system, this situation is critical because peripheral PP is usually higher than central aortic PP, located close to the heart. The aim of this system is to distribute oxygen and nutritional elements to organs and peripheral tissues, and therefore to minimize the work of the heart while maintaining peripheral perfusion. The process of PP-amplification fits with this physiological scheme: for the same peripheral pressure, the higher the amplification, the lower the central PP and the lower the after-load of the heart, hence cardiac work. 
PURPOSE
In recent years, the predictive value of 2 pulsatile parameters has been extensively studied in hypertension: aortic stiffness and pulse pressure (PP) amplification. Aortic stiffness is an index of aortic rigidity and PP-amplification is the ratio between central and brachial PP, an indirect evaluation of wave reflections. Both are safe, independent, noninvasive predictors of overall and cardiovascular risk. Our purpose is to determine the validity of these parameters in 2 different circumstances: gender and therapeutic implications.
AGE EFFECT
Studies have shown that whereas steady mean arterial pressure is significantly higher in men than in women, pulsatile pressure largely predominates in women, mostly in older age and as a consequence of short stature. Gender differences require more extensive investigation due to the disparities of dose-response ranging among populations and the contribution of ethnic factors, frequently based on individual origin.
REGARDING THERAPEUTIC IMPLICATIONS
Many questions have yet to be resolved. First, the prognosis of antihypertensive therapy is largely based on blood pressure reduction but also requires evaluation of arterial rigidity and wave reflections to achieve adequate therapeutic "de-stiffening. " The most effective approach appears to be the combination of angiotensin-and calciumchannel blockade, in certain cases associated with diuretic compounds. Second, antialdosterone drugs can be useful, but it is their antifibrotic more than their antihypertensive effect that appears effective. Third, prevention of comorbidities, such as those associating hypertension, diabetes, and/or kidney damage, should become primary targets for drug treatment. The purpose of the present review is to determine the characteristics of aortic stiffness and PP amplifications in 2 different conditions: first, under baseline situations, to evaluate aortic stiffness and PP-amplification, as predictors of CV risk in large populations; second, to determine potential differences between men and women, usually compared in both younger and older adults. From these findings, alternative therapeutic implications may be determined in hypertension and are described at the end of this report.
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Aortic stiffness
Aortic PWV is usually considered as an independent predictor of overall and CV risk, often observed in patients with end-stage renal disease (ESRD). Because age, BP, heart rate, and gender are strong determinants of both arterial stiffness and mortality, the individual relevance of PWV determinations remains controversial and requires more extensive investigations. 4 A cohort of 242 patients with ESRD, all undergoing hemodialysis, was studied over a mean period of 78 ± 46 months (±SD). At entry, stiffness was assessed using flow wave velocity measured by Doppler ultrasonography. On the basis of a multivariate analysis established in 469 nonuremic subjects, a theoretical value of PWV was determined in ESRD patients, taking into account age, BP, gender, and heart period. The PWV index (i.e., "measured" PWV minus "theoretical" PWV) was then calculated for each ESRD patient. Based on Cox analysis, the PWV index was shown to be a strong independent predictor of both CV and overall mortality, together with 2 other factors: age, and time on dialysis prior to inclusion. Patients with positive (vs. negative) PWV index had a 2-fold adjusted increased risk of mortality during the follow-up. For each 1 m/s PWV index increment, a significant 34% (crude) and 14% (adjusted) increase in both CV and overall mortality were observed.
Thus, in ESRD patients, the calculated "PWV index" was highly predictive of CV and overall mortality risk indicating that PWV measurements have a discriminatory prognostic role over and above conventional CV risk factors.
Another important investigation was performed in subjects with essential hypertension, in the absence of ESRD. The purpose was to determine whether a low-dose combination of the angiotensin-converting enzyme inhibitor, perindopril (Per), and the diuretic, indapamide (Ind), had the capacity to reduce central (thoracic aorta, carotid artery) as well as brachial SBP to a greater extent than the beta-blocker, atenolol. The second objective was to determine PWV and the pattern of wave reflections that independently influence brachial and central SBP. 5 In this double-blind randomized trial with a 1-year follow-up, for similar diastolic blood pressure (DBP) reductions, Per/Indreduced SBP significantly more than atenolol ( Figure 2 ), with more pronounced reductions for central than for brachial SBP. After 1 year, the difference between brachial and central SBP was maintained by Per/Ind (8.28 ± 1.53 mm Hg) but significantly reduced by atenolol (0.29 ± 1.61 mm Hg). With atenolol, the principal factor modulating SBP reduction was mean BP. With Per/ Ind, brachial BP played a minor role, and central SBP reduction was mainly due to reduced PWV and wave reflections. With Per/Ind, but not with atenolol, normalization of brachial SBP was achieved with a significantly greater reduction of central SBP. This hemodynamic pattern clearly showed the presence of changes in wave reflections arising from the distal arterial and arteriolar territory, where Per/Ind, but not atenolol, are known to significantly modify vessel wall structure and function.
The role of arterial stiffness on BP response to drug treatment was also studied in subjects with essential hypertension. 5 Subjects were divided into 3 tertiles according to baseline PWV and post-hoc analysis was performed. 6 After 12 months of treatment, BP differed significantly between PWV tertiles, the third having the highest PWV and the lowest BP response. Although DBP control was comparable between these 3 PWV tertiles, SBP control was significantly associated with PWV level (P = 0.001) and with treatment with Per/Ind (P < 0.001). The effect of PWV on BP response was independent of age, the need for increased drug dosages, or the presence of CV risk factors, including kidney function. 7 Thus, achieving SBP control appeared to be influenced by aortic stiffness as one of the functions of angiotensin-converting enzyme inhibition in hypertensive subjects.
In conclusion, the clinical importance of SBP in treated hypertensive subjects is well established. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Studies on aortic stiffness further support the clinical relevance of SBP, and hence PWV, not only under normal conditions, but also in the presence of aging and hypertension ( Figure 3 ). Such findings have increased our understanding of the role played by the inhomogeneity of the arterial tree and the reflected pressure waves in governing SBP. 7 Increased SBP is a recognized risk factor for CV complications, especially in older patients, but particularly when this increase is due to a stiffened arterial tree with a reduced DBP. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Early epidemiologic studies in hypertension required a DBP ≥90 mm Hg for study inclusion. These requirements necessarily included persons with high SBP but excluded those with low DBP and a wide PP.
Recently, inclusion of such patients has shown that elevated SBP and PP are strong predictors of CV risk. These considerations point to a possible re-definition of hypertension to include patients with lower DBP and to the inaccuracy, but absolute necessity, of the brachial artery BP as a surrogate for aortic BP-the pressure that the heart sees.
PP-amplification
One French study on PP-amplification sought to determine whether the carotid/brachial (C/B) ratio is an independent predictor of CV risk. 8 Brachial and carotid PP are individually recognized as independent predictors of CV risk, particularly in elderly patients. Levels of brachial and carotid PP differ significantly at their own particular site, and therefore PP-amplification, i.e., the C/B ratio, may also be an independent predictor of CV risk. The question that is raised therefore is whether brachial/carotid PP may also be an independent predictor of CV risk. In a population of 834 patients, brachial and carotid PP were measured with a sphygmomanometer and by pulse wave analysis. Using stepwise multiple regressions, carotid PP was calculated from a multivariate analysis including age, gender, body-height, brachial PP, and plasma glucose. This model was applied to 125,151 subjects. Over the 12-year-follow-up, 3,997 deaths occurred (735 of CV origin). Using Cox regression analysis, multiadjusted hazard ratios and confidence intervals were calculated for 1 SD increase in brachial PP, calculated carotid PP, and the C/B ratio. A significant association was noted between brachial PP and both CV and all-cause mortality. Calculated carotid PP predicted a similar risk. The C/B ratio was also a strong predictor of both risks (hazard ratio, 1.22; 95% confidence interval, 1.12-1.32, and hazard ratio, 1.41; 95% confidence interval, 1.14-1.73, respectively). Results were not significantly modified when drug treatment or other confounding variables were added. Thus, brachial PP, calculated carotid PP, and C/B PP-amplification were all shown to predict CV mortality. Moreover, because the C/B ratio is less dependent on BP calibration, it is directly applicable to large population studies.
The longitudinal PARTAGE study 9 assessed the predictive value of BP and PP-amplification in terms of overall mortality (primary endpoint) and major CV events in elderly individuals (mean age, 88 ± 5 years). The study included 1,126 subjects (874 women) living in nursing homes in France and Italy. C/B PP-amplification was calculated using arterial tonometry. Office and 3-day self-measurements of BP were performed. Over the 2-year follow-up, there were 247 deaths and 228 major CV events. PP-amplification was seen to be a predictor of total mortality and major CV events in this elderly population. For a 10% increase in PP-amplification, total mortality was reduced by 24% (P < 0.0003) and major CV events were reduced by 17% (P < 0.01). Investigators reported either an absence of association or an inverse correlation between SBP, DBP, and PP, and total mortality and major CV events. In these very elderly individuals, low PP-amplification from central to peripheral arteries was a powerful predictor of mortality and major CV events. Assessment of PP-amplification was an aid to risk-estimation and also improved diagnostic and therapeutic strategies in very elderly, poly-medicated individuals. However, neither high SBP nor PP were associated with a greater risk of mortality or major CV events in this population.
The last study in this review focused on PP-amplification and sought to determine whether the brachial/carotid (or carotid/brachial) PP (B/C-PP) amplification ratio may selectively predict gender specificities in age-related CV death. 10 The study included 125,151 patients (M, 72,437: age, 41.0 ± 11.1 years and F, 52,714: 39.5 ± 11.6 years). Carotid PP was calculated in men and in women by a validated multiple regression analysis including brachial PP, age, height, and risk factors. Over the 12-year follow-up, 3,997 deaths were reported (M, 3,028 and F, 969). The mortality impact of the B/C-PP ratio was 3 times greater in women than in men ≥55 years old. PP-amplification was a strong predictor of gender-related differences in CV risk. 10 In post-menopausal women, attenuated PP-amplification played a key role in the significant increase in CV risk.
In conclusion, aortic stiffness and PP-amplification are 2 distinct aspects of CV risk. The former is mainly related to aortic rigidity and the latter to changes in PP and wave reflections. There is no significant correlation between these 2 parameters, either in univariate or in multivariate analysis. 11 Elevated CV risk may occur with increased aortic stiffness, with an abnormality in one of the PP-amplification ratios or a combination of both. In this process, it is important to note that PP-amplification is strongly related to heart rate and that this parameter may have specific consequences on cardiac work. Lowering heart rate may have positive (reduction in the number of systolic contractions) or negative (reduction of amplification) effects. In this context, the interpretation of PP-amplification as a risk factor merits further discussion.
AORTIC STIFFNESS, PP-AMPLIFICATION, AND GENDER DIFFERENCES IN HYPERTENSION
A preliminary study on gender differences assessed the properties of the arterial tree to identify differences between men and women as they aged. 13 A total of 530 patients (M, 347 and F, 183) was classified into quartiles according to age: ≤40, 41-47, 48-54, and ≥55 years, with the 2 middle groups corresponding to the menopausal years. In all age-groups, heart rate was higher in women than in men but mean BP was lower. PP, however, was lower in younger women than in age-matched men and higher in older women than in age-matched men. Although measurements that are affected by body size, e.g., common carotid artery diameter, compliance, and systemic compliance, were lower in women, measurements that are related to arterial wall properties, such as carotid and aortic distensibility, were similar in both genders. With aging, aortic PWV rose to similar extents in men and women whereas in women, the influence of PWV on PP was greater than that of mean BP. The reverse was true in men. Although mean BP is lower in women than in men and arterial distensibility is similar in both genders, women nevertheless develop a higher degree of pulsatility than men with advancing age. This is likely due to smaller physical characteristics and is independent of the hormonal effects of menopause.
A second study presented evidence that short stature is a hemodynamic liability, thus partially explaining the inverse relation between body-height and CV risk. 14 Of the 402 individuals studied, 149 had ESRD and 253 had normal renal function. BP, body-height, length of the cardiac cycle, carotid-femoral PWV, and carotid artery pulse waves (by applanation tonometry), as well as arrival time of reflected waves were all measured. Based on linear and stepwise multiple regressions, a correlation was observed between body-height and all variables, with the exception of mean BP. Despite identical BP levels, the early systolic arrival of reflected waves in short people caused the aorta to stiffen and increased the pulsatile effort of the left ventricle. Faster heart rate, which increases cardiac minute work and shortens diastole, is another recognized characteristic of individuals of short stature. Stiffening lowers aortic DBP and, coupled with a shortened diastole, is likely to adversely affect myocardial blood supply. Although indirect, these data are in favor of N = 1,455 subjects) . NB, whisker/box plots: the lower and upper box limits are percentiles; internal horizontal lines indicate medians; T-bars represent range percentiles; and the circles indicate outliers. Boxes contain 50% of the data and bars contain the remainder. Note that <30 and >70 means that age is indicated in years. Reproduced with permission from European Heart Journal. 25 a physiologic hypothesis for the association between bodyheight and CV risk.
One notable study of gender differences investigated the impact of DBP on CV mortality according to SBP levels in middle-aged men and women. 15 In this age-group, it is not known whether DBP should be used in addition to SBP to assess CV risk. The study included 77,023 men and 48,480 women (age, 40-70 years). Participants had no major CV disease, were not on antihypertensive treatment and attended a CV Center for a check-up between 1972 and 1988. Mortality was assessed over an 8-to 12-year period. CV mortality increased with increasing SBP levels in both men and women. For all participants with normal SBP levels, DBP had no influence on CV mortality, even after adjustment for age and SBP. In men with systolic hypertension, the relationship between CV mortality and DBP was U-shaped, the lowest mortality rates being observed in the group with DBP 90-99 mm Hg. After adjustment for age and SBP, CV mortality rates were shown to be 73% (P < 0.02) and 65% (P < 0.001) higher in men with DBP <90 mm Hg and DBP ≥110 mm Hg, respectively. In contrast, a positive correlation was observed between DBP and CV mortality in women with systolic hypertension. Thus, gender should be considered in the classification of CV risk in middle-aged individuals according to DBP levels, particularly when SBP levels are elevated. Compared to men with a mild-to-moderately elevated DBP, the risk for men with systolic hypertension is actually greater when DBP levels are normal. For age-matched women, however, the risk is greater in those with systolic-diastolic hypertension than in those with isolated systolic hypertension.
Some of our earlier results show that dose-ranging of antihypertensive agents may differ between men and women. 16 A database compiling the data from 5 randomized, double-blind, dose-ranging studies was created to determine the optimal dose of the Per/Ind combination for the treatment of hypertension in both men and women. Two thousand nine hundred and seven patients were treated with either placebo or various combinations of Per (2, 4, or 8 mg) and Ind (0.625, 1.25, or 2.5 mg). In the overall population, a significant dose-response relationship (P < 0.001) was observed in favor of increasing doses of Per 2/Ind 0.625 mg up to Per 8/Ind 2.5 mg for progressive reductions in SBP, DBP, and mean BP. Data for men and women were analyzed separately; SBP, DBP, and mean BP (but not PP) decreased significantly more in women than in men until the Per 4/Ind 1.25 mg dosage was reached. Thereafter, with higher dosages (generating slight though significant hypokalemia), the finding was reversed, resulting in a gender interaction in the overall population. In these hypertensive individuals, the low-dose combinations Per 2/Ind 0.625 mg and Per 4/Ind 1.25 mg were the most effective antihypertensive doses that also avoided the potential risk of hypokalemia. Benefits were more notable in women, in whom elevated SBP and PP were predominant baseline hemodynamic features.
In addition to the role of gender differences on BP changes, the impact of country of birth on arterial stiffness and wave reflections was investigated in subjects living in Paris but born in France or elsewhere in Europe (67%), Africa (25%), Asia (5%), and French Overseas Departments (3%). 17 Baseline and longitudinal changes with age between 2007 and 2011 were studied in the reference group, i.e., the white French population born in Paris, and compared with those of individuals also living in Paris but who were born in Africa or Asia. Compared to those who were born in France, women who were born in African countries had significantly higher BP, cardiac mass, estimated CV risk, body mass index, cholesterol and its derivatives and glycemia. Although individuals who were born in Asia also had increased CV risk, they differed from those born in Africa or France by lower body weight and HDL-cholesterol levels, but higher triglyceridemia and heart rate. Studies of steady and pulsatile hemodynamics in both genders revealed significant age-related progression of these parameters in populations born in Africa, and predominantly significant central augmentation index interactions between gender and country of birth. These findings were observed mainly on comparisons between African-and European-born subjects; African-born women were more likely than men to have a steeper progression of central augmentation index with advancing age.
Studies comparing significant differences between men and women have reached two major conclusions. First, PP is a more important consideration than steady pressure in women, particularly older women. Second, age-related BP changes differ notably between men and women, particularly in terms of their relations with age. Extensive studies on these differences have yet to be performed, particularly with regard to the consequences of drug dose-ranging and the role of ethnic differences between men and women. Comparisons of the respective role of aortic stiffness and PP-amplification in CV risk also merit further investigation.
THERAPEUTIC IMPLICATIONS
In hypertensive subjects, CV risk reduction is mainly associated with decreases in SBP and PP. However, pharmacological studies have also investigated parallel reductions in aortic stiffness and/or wave reflections with de-stiffening therapy. 18 Figure 4 summarizes the pulse wave measurements widely used in clinical trials to reduce wave reflections and assess arterial wall stiffness. Drugs that inhibit the renin-angiotensin system are frequently combined with a diuretic or a calcium-channel blocker. These regimens provide selective long-term reduction of brachial and, even more importantly, central SBP and PP by decreasing arterial stiffness and/or modifying wave reflections.
In this context, it is important to assess the potential superiority of renin-angiotensin system blockade (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) administered with a calcium-channel blocker (A+C) over other widely used combinations of antihypertensive agents. A meta-analysis in a large number of hypertensive patients from 9 randomized controlled trials was conducted to compare the A+C treatment with other combination therapies in terms of BP reduction, clinical outcomes, and adverse events. 19 SBP and DBP reductions were not significantly different with the A+C combination therapy or with other antihypertensive combinations. However, compared with those on other combination therapies, patients taking the A+C combination had a significantly lower incidence of CV composite endpoints, including CV mortality, nonfatal myocardial infarction, and nonfatal stroke (P < 0.001), despite similar all-cause mortality (P = 0.15) and stroke rates (P = 0.09). Moreover, the A+C combination yielded a 3.10 ml/min/1.73 m 2 greater estimated glomerular filtration rate than other combinations (P < 0.001). Finally, the incidence of adverse events with A+C therapy was similar to that with other combination therapies (P = 0.34); the incidence of serious adverse events was however significantly lower (P = 0.03). This study suggests that A+C therapy is superior to the A-combinations alone and also implies that beta-blocking drugs are no better than other antihypertensive agents, except when coronary insufficiency is also present. Another important finding is that although lowering SBP and DBP remains an important objective of antihypertensive treatment, it is less so than the reduction of aortic stiffness and wave reflections with the subsequent decrease in CV events.
Although not yet fully tested in humans, 2 drugs have shown promising results in the treatment of aortic stiffness. First, the aldosterone receptor antagonist, spironolactone, administered long-term to both normotensive and hypertensive rats, reduced the age-induced increase in aortic and cardiac collagen content-an effect that increased aortic distensibility with no changes to intra-arterial pressure. 20, 21 Second, sacubitril, a vasopeptidase that inhibits both angiotensin-converting enzyme and neprilysin, blocks inactivation of the natriuretic peptides and may also reduce aortic stiffness. A clinical trial assessing sacubitril in combination with the angiotensin receptor blocker valsartan, is currently underway. 22 The severe comorbid events that occur when hypertension is associated with type 2 diabetes are different from those of each disease alone. 23 In diabetic subjects, the association with the metabolic syndrome (MetS) is defined by 3 or more of the following: abdominal obesity, hyperglycemia, hypertension, hypertriglyceridemia, and low HDLcholesterolemia. Based on the age-and gender-related relationships in the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort with parallel investigations of central hemodynamic measurements, 24 the effects of MetS were compared with those of patients with essential hypertension alone but whose mean arterial BP was the same as that of subjects with essential hypertension. Beyond brachial BP measurements, central hemodynamic parameters in MetS are known to involve increased aortic stiffness, reduced wave reflections, and increased PP-amplification, a parameter commonly associated with increased heart rate. With the exception of arterial stiffness, the observations in MetS are all opposite in direction to those observed in patients with essential hypertension in whom MetS is absent. This pulsatile hemodynamic change contributes independently to increasing age-and gender-mediated CV risk in subjects with both diabetes and hypertension, suggesting the importance of including specific clinical abnormalities to Framingham scores that may influence drug treatment in patients with both hypertension and diabetes. 25 Figure 4 . Definitions of the physiological aspects of pulsatile arterial hemodynamics and wave reflections. In the upper panel, 2 schematic representations of the pressure wave are shown: on the left, the forward and reflected wave and their summation in the ascending aorta; on the right, a typical blood pressure curve. In the bottom panel, blood pressure curves in younger (left) and in older (right) subjects are represented. Augmentation pressure (P2 in mm Hg) is the difference between peak systolic blood pressure and the top of the forward wave. Augmentation index (AIx) (the percent ratio of augmentation pressure to pulse pressure) represents the additional systolic blood pressure increase in the ascending aorta due to wave reflections. This hemodynamic profile is observed in older, but not in younger subjects. Mean arterial pressure, the mean arterial BP, corresponds to the steady component of BP. P1 and P3, systolic blood pressure and diastolic blood pressure expressed in mm Hg. Reproduced with permission from Taylor and Francis (www.tandfonline.com). 18 
